ГоловнаАрхiв номерiв2021Том 29, випуск 3 (108)Настанови з фармакологічної підтримки ранньої моторної реабілітації після гострого ішемічного інсульту Європейської академії неврології та Європейської федерації нейрореабілітаційних товариств (Переклад з англійської: Наталія Купріненко).
Назва статтi Настанови з фармакологічної підтримки ранньої моторної реабілітації після гострого ішемічного інсульту Європейської академії неврології та Європейської федерації нейрореабілітаційних товариств (Переклад з англійської: Наталія Купріненко).
Автори Ettore Beghi
Heinrich Binder
Codruta Birle
Natan Bornstein
Karin Diserens
Stanislav Groppa
Volker Homberg
Vitalie Lisnic
Maura Pugliatti
Gary Randall
Leopold Saltuari
Stefan Strilciuc
Johannes Vester
Dafin Muresanu
З рубрики ЄВРОПЕЙСЬКИЙ ДОСВІД
Рiк 2021 Номер журналу Том 29, випуск 3 (108) Сторінки 63-76
Тип статті Наукова стаття Індекс УДК Індекс ББК -
Анотацiя DOI : https://doi.org/10.36927/2079-0325-V29-is3-2021-12

Ключовi слова
Доступ до повної статтi pdf Скачати
Перелiк
використаної
лiтератури
1. Bernhardt J, Hayward KS, Kwakkel G, et al. Agreed definitions and a shared vision for new standards in stroke recovery research: the Stroke Recovery and Rehabilitation Roundtable Taskforce. Int J Stroke. 2017;12(5):444-450. https://doi.org/10.1177/1747493017 711816
2. Dobkin BH. Clinical practice. Rehabilitation after stroke. N Engl J Med. 2005;352(16):1677-1684. https://doi.org/10.1056/NEJMc p043511
3. Gorelick PB. The global burden of stroke: persistent and disabling. Lancet Neurol. 2019;18(5):417-418. https://doi.org/10.1016/S1474-4422(19)30030-4
4. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. https://doi.org/10.1136/bmj.39489.470347.AD
5. Leone MA, Brainin M, Boon P, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces-revised recommendations 2012. Eur J Neurol. 2013;20(3):410-419. https://doi.org/10.1111/ene.12043
6. Leone MA, Keindl M, Schapira AH, Deuschl G, Federico A. Practical recommendations for the process of proposing, planning and writing a neurological management guideline by EAN task forces. Eur J Neurol. 2015;22(12):1505-1510. https://doi.org/10.1111/ene.12818
7. Higgins H, van Limbeek J, Geurts A, Zwarts M. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds.), Cochrane Handbook for Systematic Reviews of Interventions. 6.2. The Cochrane Collaboration; 2011 8. Hsu C-C, Sandford B. The Delphi technique: making sense of consensus. Pract Assess Res Eval. 2019;12(1):1-5. https://doi.org/ 10.7275/pdz9-th90
9. Sprigg N, Willmot MR, Gray LJ, et al. Amphetamine increases blood pressure and heart rate but has no effect on motor recovery or cerebral haemodynamics in ischaemic stroke: a randomized controlled trial (ISRCTN 36285333). J Hum Hypertens. 2007;21(8):616-624. https://doi.org/10.1038/sj.jhh.1002205
10. Sonde L, Nordstrom M, Nilsson CG, Lokk J, Viitanen M. A doubleblind placebo-controlled study of the effects of amphetamine and physiotherapy after stroke. Cerebrovasc Dis. 2001;12(3):253-257. https://doi.org/10.1159/000047712
11. Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present-a pharmacological and clinical perspective. J Psychopharmacol (Oxford). 2013;27(6):479-496. https://doi.org/10.1177/0269881113482532
12. Muresanu DF, Heiss W-D, Hoemberg V, et al. Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial. Stroke. 2016;47(1):151-159. https:// doi.org/10.1161/STROKEAHA.115.009416
13. Guekht A, Vester J, Heiss W-D, et al. Safety and efficacy of cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials. Neurol Sci. 2017;38(10):1761-1769. https://doi. org/10.1007/sl0072-017-3037-z
14. Amiri-Nikpour MR, Nazarbaghi S, Ahmadi-Salmasi B, Mokari T, Tahamtan U, Rezaei Y. Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatr Dis Treat. 2014;10:2299-2306. https://doi.org/10.2147/NDT.S75304
15. Stan A, Birle C, Blesneag A, Iancu M. Cerebrolysin and early neurorehabilitation in patients with acute ischemic stroke: a prospective, randomized, placebo-controlled clinical study. J Med Life. 2017;10(4):216-222
16. Chang WH, Park C, Kim DY, et al. Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke. BMC Neurology. 2016;16(1):31. https://doi.org/10.1186/sl2883-016-0553-z
17. Bornstein NM, Guekht A, Vester J, et al. Safety and efficacy of cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018;39(4):629-640. https:// doi.org/10.1007/sl0072-017-3214-C
18. Acler M, Robol E, Fiaschi A, Manganotti P. A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. J Neurol. 2009;256(7):1152-1158. https://doi.org/10.1007/s0041 5-009-5093-7
19. Savadi Oskouie D, Sharifipour E, Sadeghi Bazargani H, et al. Efficacy of citalopram on acute ischemic stroke outcome: a randomized clinical trial. Neurorehabil Neural Repair. 2017;31(7):638-647. https:// doi.org/10.1177/1545968317704902
20. Kraglund KL, Mortensen JK, Damsbo AG, et al. Neuroregeneration and vascular protection by citalopram in acute ischemic stroke (TALOS). Stroke. 2018;49(11):2568-2576. https://doi.org/10.1161/ STROKEAHA.117.020067
21. Gladstone DJ, Danells CJ, Armesto A, et al. Physiotherapy coupled with dextroamphetamine for rehabilitation after hemiparetic stroke: a randomized, double-blind, placebo-controlled trial. Stroke. 2006;37(1):179-185. https://doi.org/10.1161/01.STR.0000195169. 42447.78
22. Louise M, Gunnar WN. Safety of dexamphetamine in acute ischemic stroke. Stroke. 2003;34(2):475-481. https://doi.org/10.1161/01. STR.0000050161.38263.AE
23. Yu M, Sun Z-J, Li L-T, Ge H-Y, Song C-Q, Wang A-J. The beneficial effects of the herbal medicine Di-Huang-Yin-Zi (DHYZ) on patients with ischemic stroke: a randomized, placebo controlled clinical study. Complement Ther Med. 2015;23(4):591-597. https://doi. org/10.1016/j.ctim.2015.06.003
24. Chollet F, Cramer SC, Stinear C, et al. Pharmacological therapies in post stroke recovery: recommendations for future clinical trials. J Neurol. 2014;261(8):1461-1468. https://doi.org/10.1007/s00415-013-7172-z
25. Asadollahi M, Ramezani M, Khanmoradi Z, Karimialavijeh E. The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. Clin Rehabil. 2018;32(8):1069-1075. https://doi.org/10.1177/0269215518777791
26. Dennis M, Mead G, Forbes J, et al. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet. 2019;393(10168):265-274. https://doi.org/10.1016/S0140-6736(18)32823-X
27. Lundstrom E, Isaksson E, Nasman P, et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(8):661- 669. https://doi.org/10.1016/S1474-4422(20)30219-2
28. AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(8):651- 660. https://doi.org/10.1016/S1474-4422(20)30207-6
29. Mohammadianinejad SE, Majdinasab N, Sajedi SA, Abdollahi F, Moqaddam MM, Sadr F. The effect of lithium in post-stroke motor recovery: a double-blind, placebo-controlled, randomized clinical trial. Clin Neuropharmacol. 2014;37(3):73-78. https://doi. org/10.1097/WNF.0000000000000028
30. Albert U, De Cori D, Blengino G, Bogetto F, Maina G. Lithium treatment and potential long-term side effects: a systematic review of the literature. Riv Psichiatr. 2014;49(1):12-21. https://doi. org/10.1708/1407.15620
31. Chen CLH, Young SHY, Gan HH, et al. Chinese medicine neuroaid efficacy on stroke recovery: a double-blind, placebo-controlled, randomized study. Stroke. 2013;44(8):2093-2100. https://doi. org/10.1161/STROKEAHA.113.002055
32. Di Cesare F, Mancuso J, Woodward P, Bednar MM, Loudon PT, A9541004 Stroke Study Group. Phosphodiesterase-5 inhibitor PF- 03049423 effect on stroke recovery: a double-blind, placebo-controlled randomized clinical trial. J Stroke Cerebrovasc Dis. 2016;25(3):642-649. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.11.026
33. Sivenius J, Sarasoja T, Aaltonen H, Heinonen E, Kilkku O, Reinikainen K. Selegiline treatment facilitates recovery after stroke. Neurorehabil Neural Repair. 2001;15(3):183-190. https://doi. org/10.1177/154596830101500305
34. Wieloch T, Nikolich K. Mechanisms of neural plasticity following brain injury. Curr Opin Neurobiol. 2006;16(3):258-264. https://doi. org/10.1016/j.conb.2006.05.011
35. Muresanu DF, Buzoianu A, Florian SI, von Wild T, Muresanu D. Towards a roadmap in brain protection and recovery. J Cell Mol Med. 2012;16(12):2861-2871. https://doi.org/10.1111/j.1582-4934.2012.01605.x
36. Sahota P, Savitz SI. Investigational therapies for ischemic stroke: neuroprotection and neurorecovery. Neurotherapeutics. 2011;8(3):434-451. https://doi.org/10.1007/s13311-011-0040-6
37. Muresanu DF, Florian S, Homberg V, et al. Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial. NeurolSci. 2020;41(5):1171- 1181. https://doi.org/10.1007/s10072-019-04181-y
38. Muresanu DF, Buzoianu A, Florian SI, von Wild T. Towards a roadmap in brain protection and recovery. J Cell Mol Med. 2012;16(12):2861-2871. https://doi.org/10.1111/j.1582-4934.2012.01605.x 39. Riley C, Hutter-Paier B, Windisch M, Doppler E, Moessler H, Wronski R. A peptide preparation protects cells in organotypic brain slices against cell death after glutamate intoxication. J Neural Transm. 2006;113(1):103-110. https://doi.org/10.1007/s00702-005-0302-8
40. Wronski R, Tompa P, Hutter-Paier B, Crailsheim K, Friedrich P, Windisch M. Inhibitory effect of a brain derived peptide preparation on the Ca++-dependent protease, calpain. J Neural Transm (Vienna). 2000;107(2):145-157. https://doi.org/10.1007/s007020050013
41. Siepmann T, Penzlin AI, Kepplinger J, et al. Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. Brain Behav. 2015;5(10):e00373. https://doi.org/10.1002/brb3.373
42. McCann SK, Cadi I, Mead GE, et al. Efficacy of anti depressants in animal models of ischemic stroke. Stroke. 2014; 45(10):3055-3063. https://doi.org/10.1161/STROKEAHA.114.006304
43. Mead GE, Hsieh C-F, Lee R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012;11:CD009286. https://doi.org/10.1002/14651858.CD009286.pub2
44. Ziganshina LE, Abakumova T, Vernay L. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2016;12:CD007026. https://doi.org/10.1002/14651858.CD007026.pub4
45. Hiroki A, Susumu J, Takuya T. Pharmacological enhancement of stroke rehabilitation. Stroke. 2019;50(11):3323-3329. https://doi. org/10.1161/STROKEAHA.119.023720